在阿尔茨海默病中使用机器学习分类器对动图的诊断性能 - 一个横截面记忆诊所研究研究
Mathias Holsey Gramkow1, Andreas Brink-Kjær2,3, Frederikke Kragh Clemmensen4
1Danish Dementia Research Centre, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, Inge Lehmans Vej 8, Copenhagen, DK-2100, Denmark. mathias.holsey.gramkow@regionh.dk.
Alzheimer's research & therapy
|May 21, 2025
概括
使用可穿戴传感器的动图学可以检测阿尔茨海默病 (AD) 运动和昼夜节律的变化. 机器学习分析的actigraphy数据显示,在区分痴呆类型方面有希望.
科学领域:
- 老年学是一门学科.
- 神经学 神经学
- 生物医学工程 生物医学工程
背景情况:
- 阿尔茨海默病 (AD) 与改变的运动模式,活动水平和昼夜节律有关.
- 使用可穿戴传感器的动图学提供了一种评估这些变化的方法.
- 在区分痴呆症亚型方面,动图的诊断实用性尚未完全确定.
研究的目的:
- 为了评估在记忆诊所人群中识别阿尔茨海默病 (AD) 的诊断性能.
- 评估在动图学数据上训练有素的机器学习分类器在AD和其他痴呆病因之间区分能力.
主要方法:
- 一项横截面研究包括70名患有阿尔茨海默病,勒维体痴呆症 (DLB),脑血管疾病 (CVD) 的患者,以及48名健康对照.
- 参与者在一个星期内佩戴了两个身上的传感器,以收集加速度计数据.
- 使用后勤回归的机器学习分类器在510个活动相关特征上受训,这些特征来自运动模式和昼夜节律数据.
主要成果:
- 两组之间观察到运动模式和昼夜节律强度/碎片化的显著差异.
- 与对照人群相比,动图学数据显示,阿兹海默症患者的中度活动和步行减少.
- 机器学习分类器在区分痴呆病因方面实现了80-89%的准确性和69-84%的精度.
结论:
- 动图学数据,特别是用机器学习分析时,可以准确地区分不同类型的痴呆症.
- 在怀疑AD的患者中,动图显示出作为差异诊断的补充工具的潜力.
相关概念视频
Alzheimer's Disease: Overview
409
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
409
Alzheimer's Disease: Treatment
141
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
141


